Median overall survival for patients with newly diagnosed multiple myeloma may surpass ten years. Nonetheless, many patients face considerable treatment-related morbidity and relapsed disease. Owing to this typically long overall survival, most multiple myeloma trials now use progression-free survival as their primary end point. In this Comment, we highlight circumstances in which this end point does not best answer the questions that various trials seek to investigate.

中文翻译：

---

总生存期作为多发性骨髓瘤试验的主要终点

新诊断的多发性骨髓瘤患者的中位总生存期可能超过十年。尽管如此，许多患者面临相当大的与治疗相关的发病率和疾病复发。由于这种通常较长的总生存期，大多数多发性骨髓瘤试验现在使用无进展生存期作为其主要终点。在此评论中，我们强调了该终点不能最好地回答各种试验试图调查的问题的情况。